P&U Loses Wrangle Over OTC Minoxidil Pharmacia & Upjohn was denied a court order that would have blocked the sale of generic versions of over-the-counter Rogaine (minoxidil), its hair-growth product. The company was asking for a three-year extension of its exclusive marketing of OTC Rogaine; the extension would have overturned a US Food and Drug Administration ruling allowing generic minoxidil to be sold immediately.
Three companies are now cleared to sell Rogaine in generic form - Lemmon, Alpharma and Bausch & Lomb. Alpharma's Barre-National division already had $3 million in orders and 200,000 bottles of minoxidil to go and, reportedly, after verbal notification from the FDA, B-N has resumed shipping the product.
Noting the firm's disappointment, a P&U spokesman said legal options will now be explored, but did not give further details. P&U had forecast sales of about $1 billion for OTC Rogaine, but says without the injunction this could drop to $655 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze